FridayJul 10, 2026 10:00 am

New Vaccine Gives Brain Cancer Patients Hope of Longer Survival

Traditionally, vaccines have been used as a way to prevent many diseases, such as the childhood vaccines used to prevent measles. However, scientists are now developing therapeutic vaccines that can be given to cancer patients in order to slow or reverse the progression of the malignancy. One such vaccine was recently developed in Germany and the results offer cautious hope for patients with deadly brain tumors. In a study that was published in the Nature journal, the scientists described their small trial that involved 33 patients diagnosed with high-grade astrocytomas. These tumors usually recur and progress to a level that…

Continue Reading

ThursdayJul 09, 2026 10:00 am

Understanding Why Treatment Resistance Exists in Many Cancers

One of the biggest challenges that the medical community faces in fighting cancer is the treatment resistance phenomenon. Treatment resistance results in poor prognosis for patients due to the inability of available treatments to deliver meaningful beneficial changes in cancer progression. We discuss some of the mechanisms that have been studied as scientists search for a solution to treatment resistance in cancer patients. For starters, it has now become clear that treatment resistance can be broadly categorized into two distinct groups. The first is primary/innate/intrinsic resistance, in which from the get-go, a patient doesn’t respond to the available cancer treatments…

Continue Reading

ThursdayJul 09, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Targets Biotech’s Manufacturing Bottleneck with AI-Powered GMP Platform

Oncotelic has launched an AI-powered GMP manufacturing services platform that integrates its PDAOAI(TM) architecture, digital batch records, and intelligent robotics built with partner TechForce Robotics The platform targets emerging biotechs, CDMOs, cell and gene therapy developers, and radiopharmaceutical manufacturers that cannot justify building full GMP infrastructure in-house The same AI-GMP capabilities already run inside Oncotelic's SAPU manufacturing base, positioning the launch as both a pipeline accelerator and a potential new revenue line For emerging biotechnology companies, the road from promising science to clinical execution often breaks down in the same place: manufacturing. Discovery can begin in a university lab, a…

Continue Reading

WednesdayJul 08, 2026 10:30 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies. ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA's lead therapeutic candidate. The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing. VERAXA's BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move…

Continue Reading

WednesdayJul 08, 2026 9:45 am

Earth Science Tech Inc. (ETST) Is Building on Unique Competitive Advantages to Deliver Steady Growth

Earth Science Tech acquires, operates, optimizes, and manages autonomous revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate development This approach has created a “conglomerate” business model that separates ETST from other healthcare companies and enables the company to capture the profit margins at every step that other companies are forced to outsource ETST’s competitive advantages include its end-to-end vertical integration that covers all aspects of patient care (consultation, pharmacies, and fulfillment) as well as the provision of B2B tech and real estate This vertical integration has resulted in direct revenue growth while continually building the company’s product pipeline Earth…

Continue Reading

TuesdayJul 07, 2026 10:00 am

Supreme Court Ruling Could Worsen the US Healthcare Crisis

There is general agreement that the healthcare system in the U.S. is in crisis, and a recent ruling issued by the Supreme Court could worsen the situation. This particular ruling allowed the federal government to end the TPS (temporary protected status) of noncitizens from particular countries, in this case Syria and Haiti. Under the TPS law that was passed back in 1990, the government, through Homeland Security, could grant temporary protected status to noncitizens from listed countries if those countries were deemed to be unsafe for their citizens in the U.S. to go back. The grounds for granting this status…

Continue Reading

TuesdayJul 07, 2026 9:45 am

The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics

Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration. Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C from Regentis is a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows. With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is targeting a multi-billion-dollar market where providers, payers and patients are seeking more practical regenerative solutions. What begins as a localized cartilage defect can ultimately evolve into a significant…

Continue Reading

MondayJul 06, 2026 10:00 am

UCS Unveils Tool to Track Attacks Against Science in the US

The Union of Concerned Scientists (UCS) has unveiled an interactive tool geared toward documenting and highlighting the different ways through which science has come under attack from the time Trump took office for the second time. The tool also documents possible violations of draft legislation before Congress, called the Scientific Integrity Act.  The tool, dubbed Attacks on Science Tracker, so far has a total of 576 attacks against science and 188 incidents that are categorized as possible violations of the Scientific Integrity Act. These cases span from January 2025 up to June 29, 2026.  The developers of the tool aimed to bring to the public’s attention the different ways through which political and elected…

Continue Reading

ThursdayJul 02, 2026 10:00 am

Comprehensive Review Shows Gut Microbiome Influences Immunotherapy Efficacy

Scientists have for long been concerned about why some people with liver cancer respond when given immunotherapy but others don’t. A recent comprehensive review provides key insights linking how patients respond to these treatments to the status of their gut microbiome.  The review, published in the journal Cancer Biology and Medicine, was conducted by a team based at the Chinese University of Hong Kong. The scientists compiled recent scientific data detailing how the microbial composition of the gut impacts how different patients respond when they are given immune checkpoint blockade therapies against hepatocellular carcinoma, the most common type of liver cancer.  They found that anti-tumor immune activity is modulated or influenced…

Continue Reading

WednesdayJul 01, 2026 10:40 am

Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical companies continuing to commit substantial capital to preclinical and early-stage innovation. The Jazz Pharmaceuticals–AbCellera collaboration illustrates how differentiated antibody technologies can command significant financial commitments before entering clinical development. VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two therapeutic modalities that continue to attract strategic partnerships and acquisitions. Platform technologies and individual drug candidates both represent potential avenues for future partnering, licensing, and collaboration agreements. Recent transactions across the sector demonstrate that pharmaceutical companies are actively seeking access to…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000